Clinical Trials Logo

Clinical Trial Summary

The aim of the study is to retrospectively evaluate the outcome of adjuvant concurrent chemoradiation delivered to patients with high grade non-metastatic soft tissue sarcomas of the extremities at the investigators institution paired with patients treated by adjuvant radiation therapy

Clinical Trial Description


Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

NCT number NCT02994264
Study type Observational
Source Institut de Cancérologie de Lorraine
Status Completed
Phase N/A
Start date August 2015
Completion date January 2016

See also
  Status Clinical Trial Phase
Recruiting NCT04577014 - INCMGA00012 (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Completed NCT01949506 - (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas N/A
Recruiting NCT04595994 - Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma Phase 1
Recruiting NCT04122872 - GISAR German Interdisciplinary Sarcoma Registry
Recruiting NCT04910126 - Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma Phase 2
Recruiting NCT04219202 - Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion N/A
Recruiting NCT04172805 - Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma Phase 2
Recruiting NCT04887298 - Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases Phase 1/Phase 2
Completed NCT01985295 - Combined Modality Treatment of Sarcomas of the Extremities Phase 1
Recruiting NCT04347122 - Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction Phase 4
Recruiting NCT04216953 - MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT04605770 - Pemetrexed, Cisplatin With Soft Tissue Sarcoma Phase 2
Recruiting NCT03474094 - Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy Phase 2
Not yet recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Suspended NCT04248959 - Prehabilitation to Improve Cancer Surgery Outcomes in AYA Patients With Extremity Sarcomas N/A